Asia’s Outsized Role in U.S. Pharma: Structuring Cross-Border Deals Amid Capital Controls, IP, and Antitrust Scrutiny

Tue, May 12 | 04:10 PM - 04:50 PM

Session details:

  • How Asian capital, biopharma innovation, and government priorities are reshaping U.S. licensing, partnerships, and M&A activity
  • Structuring cross-border deals to manage capital controls, IP ownership, data transfer, and freedom-to-operate risk
  • Anticipating antitrust and regulatory scrutiny early to avoid delays, value erosion, or post-signing renegotiation

Speakers:

Monika Vnuk
Monika Vnuk Senior Vice President, Global Head of Partnering and Business Development Sanofi
Claris Tsang Munksgaard
Claris Tsang Munksgaard Global Business Development and Licensing EMD Serono, Inc
Nikhil Mutyal
Nikhil Mutyal Head of Search and Evaluation - Respiratory & Immunology Head of Search and Evaluation - Respiratory & Immunology AstraZeneca
John Gustofson
John Gustofson President Head of Chugai Venture Fund
Track:
BD&L